Quick Answer
Relay Therapeutics, Inc. reported Operating Income Loss of -$302.74 million for the year ending 2025.
- Relay Therapeutics, Inc. showed an increase of +18.7% in Operating Income Loss from 2024 to 2025.
- This data is from Relay Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 7 years of available data (2019 to 2025), Relay Therapeutics, Inc.'s Operating Income Loss has declined by 260.2%.
- Historical annual values: Fiscal year 2025: -$302.74 million | Fiscal year 2024: -$372.47 million | Fiscal year 2023: -$373.00 million | Fiscal year 2022: -$299.28 million | Fiscal year 2021: -$364.70 million | Fiscal year 2020: -$55.80 million | Fiscal year 2019: -$84.05 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: